Puma Biotechnology CFO sells shares value $32,232

Maximo F. Nougues, Chief Monetary Officer of Puma Biotechnology, Inc. (NASDAQ:PBYI), a worthwhile biotech firm at the moment valued at $144 million with a P/E ratio of 6.14, lately bought 10,227 shares of widespread inventory. The transaction, which befell on January 2, 2025, was executed at a weighted common worth of $3.1517 per share, leading to a complete worth of roughly $32,232. Following this sale, Nougues retains possession of 152,295 shares within the firm. The sale was a part of a pre-established buying and selling plan beneath Rule 10b5-1, adopted on December 14, 2020. In accordance with InvestingPro evaluation, PBYI at the moment trades beneath its Honest Worth, with a GREAT monetary well being rating. InvestingPro subscribers can entry 6 further key insights and a complete Professional Analysis Report, a part of their protection of 1,400+ US shares.

In different latest information, Puma (OTC:PMMAF) Biotechnology has been making vital strides in its operations. The corporate’s third-quarter income for 2024 noticed a considerable enhance, reaching $80.5 million, up from $51.6 million in the identical interval final 12 months. This development was primarily pushed by the gross sales of NERLYNX, Puma’s flagship product, and a marked surge in royalty income as a result of its efficiency within the Chinese language market.

Puma Biotechnology’s profile was lately bolstered by an endorsement from the Nationwide Complete Most cancers Community (NCCN), updating its Medical Follow Tips in Oncology for Cervical Most cancers to incorporate Puma’s Nerlynx as a remedy possibility. This advice is restricted for sufferers with HER2-mutated tumors to make use of Nerlynx for recurrent or metastatic illness as a second-line or subsequent remedy.

In accordance with H.C. Wainwright, this new improvement might positively impression Nerlynx gross sales, though no modifications to gross sales forecasts have been made right now. Present estimates for internet Nerlynx gross sales stand at $46.4 million for the fourth quarter of 2024, with projected internet product gross sales of $187.2 million for the total 12 months 2024 and $195.3 million for 2025. These are latest developments that present a glimpse into Puma Biotechnology’s ongoing operations and future prospects.

This text was generated with the help of AI and reviewed by an editor. For extra info see our T&C.